Business
Pharvaris to Present in Upcoming March Investor Conferences
ZUG, Switzerland, March 02, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor
About this update from Pharvaris N.v.
[{"type":"text","content":"ZUG, Switzerland, March 02, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced that management will participate in two upcoming investor conferences in March: BioCapital Europe 2023Format: Live In-Person PresentationDate/Time: Thursday, March 9, 2023, at 11:00 a.m. CET (5:00 a.m. EST)Location: Amsterdam, Netherlands Oppenheimer 33rd Annual Healthcare ConferenceFormat: Webcasted Virtual PresentationDate/Time: Monday, March 13, 2023, at 2:00 p.m. CET (8:00 a.m. EST)Location: Virtual A live audio webcast of the Oppenheimer 33rd Annual Healthcare Conference presentation will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations. A replay will be available on Pharvaris’ website for 30 days following the presentation. About PharvarisPharvaris is a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in HAE. By directly targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE safe, effective, and convenient alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit https://pharvaris.com/. ContactMaryann CiminoDirector of Corporate [email protected] +1-617-710-7305 \nSource: Pharvaris N.V.","length":4240,"tagName":"div"}]